On E13.5, pregnant females were i.v. injected with a single dose of 400 µg anti-IFN receptor 1 (αIFNAR; MAR1-5A3 [60 (link)], Bio X Cell, NH, USA) or control IgG (IgG1; MOPC-21, Bio X Cell, NH, USA) in 150 µl PBS. After 1 day, on E14.5, the treated females were injected with poly(I:C) or PBS, as described above.
Igg1 mopc 21
Manufactured by BioXCell
Sourced in United States
IgG1 (MOPC-21) is a mouse monoclonal antibody that belongs to the IgG1 isotype. It is a commonly used control antibody in various immunological experiments and assays.
Automatically generated - may contain errors
Lab products found in correlation
Anti il 17 mab clone 17f3, by BioXCell (2 mentions)
αifnar mar1 5a3, by BioXCell (1 mentions)
Anti il 4 11b11, by BioLegend (1 mentions)
Anti ifn γ xmg1, by BioLegend (1 mentions)
Anti tgf β 1 2 3 1d11, by R&D Systems (1 mentions)
Anti il 17a 17f3, by BioXCell (1 mentions)
Il 23, by R&D Systems (1 mentions)
4 protocols using igg1 mopc 21
1
Modulating IFN Receptor for Poly(I:C) Response
2
Th22 Cell Adoptive Transfer for Allergy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Naive CD4+ T cells from spleens of DO11.10 TCR transgenic mice were magnetically sorted using naive CD4+ T cell isolation kit, mouse (Miltenyi Biotec). Next, these cells were cultured in plate-bound antibodies against CD3 (145-2C11; 2 µg/ml; eBioscience) and soluble anti-CD28 (PV-1; 2 µg/ml; BioLegend), in the presence of IL-23 (40 ng/ml; R&D Systems), anti–IL-4 (11B11; 10 µg/ml; BioLegend), anti–IFN-γ (XMG1.2; 10 µg/ml; BioLegend), and anti–TGF-β1,2,3 (1D11; 10 µg/ml; R&D Systems) neutralizing antibodies to generate Th22 cells for 5 d. After extensive washings, 5 × 106 polarized T cells were adoptively transferred i.v. to naive WT or Il22−/− recipients, which were challenged the same day by EC sensitization with OVA (100 µg/100 µl PBS). For in vivo IL-17A neutralization, anti–IL-17A (17F3; 500 µg/ml; BioXCell) neutralizing antibodies or Control IgG1 (MOPC-21; 500 µg/ml; BioXCell) was i.p. injected 1 h before and 48 h after OVA challenge. 7 d later, the challenged skins were examined by histology and immunohistochemistry.
3
Nasally Vaccinated Mice Against Brucella
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
BALB/c mice nasally vaccinated on day 0 with ΔznuA B. melitensis (n = 18), RB51 (n = 20), or PBS (n = 20); IFN-γ−/− mice were also vaccinated with ΔznuA B. melitensis (n = 10), RB51 (n = 8), or PBS (n = 9). To measure the relative contribution of CD4+ and CD8+ T cells, CD4−/− and CD8−/− mice were nasally vaccinated on day 0 with ΔznuA B. melitensis (n=8), Rev-1 (n=8), or PBS (n=8). Mice were rested for 6 wks and then challenged nasally with wt B. melitensis strain 16M. Four weeks after virulent challenge, individual spleens and lungs were recovered, subjected to homogenization and lysis as described above, and CFUs were enumerated.
To assess the role of IL-17 in protection against B. melitensis challenge in vaccinated BALB/c and IFN-γ−/− mice, IL-17 was neutralized in vivo upon treatment with 250 μg/dose of anti-IL-17 mAb (clone 17F3; BioXcell, West Lebanon, NH) on days −1, 0, 7, 14, and 21 after challenge. Control animals were similarly treated using IgG1 (MOPC-21; BioXcell) isotype control Ab instead.
To assess the role of IL-17 in protection against B. melitensis challenge in vaccinated BALB/c and IFN-γ−/− mice, IL-17 was neutralized in vivo upon treatment with 250 μg/dose of anti-IL-17 mAb (clone 17F3; BioXcell, West Lebanon, NH) on days −1, 0, 7, 14, and 21 after challenge. Control animals were similarly treated using IgG1 (MOPC-21; BioXcell) isotype control Ab instead.
4
Nasally Vaccinated Mice Against Brucella
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!